New level of antimicrobial efficacy
Next level treatment for Diabetic Foot infections
AtbFinder helps to select antibiotics against incurable multi-drug resistant bacterial and fungal pathogens
July 15, 2020
May 13, 2017
June 14, 2016
Who We Are & What We Do
TGV-Biomed is an innovative biopharmaceutical company dedicated to the development of breakthrough therapies for diabetic foot ulcers and other infected skin injuries. TGV-Biomed’s pipeline comprised of antimicrobial products based on first-in-class topical antimicrobial drug candidate Mul-1867. Mul-1867 has demonstrated prominent antibacterial efficacy against a broad range of multiresistant Gram-negative and Gram-positive bacteria, fungi and their associated biofilms as well as against mixed infections.
Microbial biofilms is the fundamental reason that diabetic foot ulcers do not heal and those formed by multiresistant microorganisms which respond very poorly to conventional antibiotic therapy are the reason for a high mortality and amputations among patients.
LEARN MORE ABOUT TGV-BIOMED
We facilitate our efforts to bring to market our life-changing breakthroughs and to alleviate the suffering of patients affected by diabetic foot infections.
Our Value Proposition
TGV-Biomed has developed a single breakthrough novel drug candidate to treat all the infections associated with diabetic foot ulcers. Mul-1867 is the first antimicrobial being developed against bacterial and fungal skin and soft tissue infections, including those caused by multidrug-resistant microorganisms.